While one could argue that the strategy is the same, the execution of that strategy is very different under Li versus Steipp. First, by saying "some manufacturing contracts outside of CE" I didn't mean low lying fruit like an overpriced pocket knife. From all indications, Li is pursuing contracts in medical and automotive. Second, LQMT has more BMG machines, more BMG formulations, and different types of BMG formulations under Li than under Steipp - i.e. Li is executing his strategy different than Steipp did. Third, under Li LQMT is offering manufacturing capabilities outside of BMG. In short, Li is not going down the same road that Steipp did.
Market Data 
Markets 
AI
